KOSDAQ-listed company Neofect will merge its wholly owned subsidiary, Weber Instrument, through an absorption-type merger. This strategic move aims to maximize synergy between the two companies and strengthen their global competitiveness in the medical beauty tech sector.
On October 15, Neofect held a board meeting and resolved to proceed with the absorption merger of Weber Instrument, announcing this decision on October 16. The merger is scheduled to take effect on January 1, 2026. Upon completion, Neofect will remain as the surviving entity, while Weber Instrument will be dissolved.
This merger serves as groundwork to maximize synergy by integrating the technology, human resources, and business infrastructure of both companies. After the merger, Neofect will oversee global strategy, marketing, distribution, and sales, while Weber Instrument will be incorporated as a business division focusing on device development, design, production, and product advancement.
The board stated, "By combining the global networks and competitive strengths in the healthcare device sector that both companies have accumulated, this is a preparatory step toward becoming a comprehensive global medical beauty tech company, covering everything from the production of raw materials based on polynucleotides (PN) and polydeoxyribonucleotides (PDRN) to device manufacturing. It is a strategic decision to maximize synergy by integrating dispersed capabilities and to efficiently restructure the business model."
Weber Instrument, which has primarily focused on the domestic market, is a medical device specialist known for its outstanding technological prowess. In terms of technology, some even say it surpasses Neofect, which has won multiple CES Innovation Awards. At one point, Weber Instrument held a 70% share of the domestic extracorporeal shock wave therapy (ESWT) device market and has since expanded its product lineup to include beauty devices in addition to traditional medical devices. Notably, its piezo-type ESWT device, the first of its kind developed in Korea, has made a significant impact in the skin aesthetics field.
Within the company, there are high expectations that this merger will accelerate global market expansion. Neofect operates local subsidiaries in the United States and Germany and maintains a dealer network in 21 countries worldwide. In particular, over 700 key hospitals, including the National Rehabilitation Center and Stanford Medical Healthcare Hospital, are considered critical footholds for global market entry.
If Neofect, with its diverse sales channels, incorporates Weber Instrument’s technology, there is a strong possibility that the company will be reborn as a "full lineup company" equipped with technology, production, and distribution capabilities.
A Neofect representative stated, "This absorption merger is the 'first stage of vertical integration in medical beauty tech,' and will serve as a trigger to maximize integrated synergy in line with the upcoming production schedule of PDRN and PN raw materials. Currently, our existing healthcare devices are being upgraded while expanding their application to aesthetic beauty devices." He added, "We plan to sequentially launch home care products optimized for skin aesthetics and anti-aging, and further enhance profitability by integrating with a dermacosmetic platform."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
